VPA response in SMA is suppressed by the fatty acid translocase CD36. (Q34306857)

1 August 2017

VPA response in SMA is suppressed by the fatty acid translocase CD36. (English)

1 reference

1 August 2017

0 references

11

Oliver Brüstle

1 reference

1 August 2017

Lutz Garbes

1

1 reference

1 August 2017

Ludwig Heesen

2

1 reference

1 August 2017

Irmgard Hölker

3

1 reference

1 August 2017

Tim Bauer

4

1 reference

1 August 2017

Julia Schreml

5

1 reference

1 August 2017

Katharina Zimmermann

6

1 reference

1 August 2017

Michaela Thoenes

7

1 reference

1 August 2017

Michael Walter

8

1 reference

1 August 2017

John Dimos

9

1 reference

1 August 2017

Michael Peitz

10

1 reference

1 August 2017

Raoul Heller

12

1 reference

1 August 2017

Brunhilde Wirth

13

1 reference

1 August 2017

16 October 2012

1 reference

1 August 2017

Human Molecular Genetics

1 reference

1 August 2017

22

1 reference

1 August 2017

2

1 reference

1 August 2017

398-407

1 reference

Spinal muscular atrophy. 32nd ENMC International Workshop. Naarden, The Netherlands, 10-12 March 1995.

1 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Differences in SMN1 allele frequencies among ethnic groups within North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Identification and characterization of a spinal muscular atrophy-determining gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Sequence of a 131-kb region of 5q13.1 containing the spinal muscular atrophy candidate genes SMN and NAIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Correlation between severity and SMN protein level in spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Phase II open label study of valproic acid in spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Valproic acid increases SMN levels in spinal muscular atrophy patient cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Induction of pluripotent stem cells from fibroblast cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Mechanisms of action of valproate: a commentatory

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

The Human Scavenger Receptor CD36: glycosylation status and its role in trafficking and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Unusual triad due to a bilateral medial medullary infarction in a 35-year-old man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

The promise of induced pluripotent stem cells in research and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Induced pluripotent stem cells from a spinal muscular atrophy patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

BAC transgenesis in human embryonic stem cells as a novel tool to define the human neural lineage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

The role of histone acetylation in SMN gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Treatment of spinal muscular atrophy by sodium butyrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS437

21 January 2018

Identifiers

DOI

10.1093/HMG/DDS437

1 reference

release_2k4cv2oexbew5nfg4cxxvugv3a

1 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2k4cv2oexbew5nfg4cxxvugv3a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference